Comparing two blood clotting tests for cirrhosis patients with bleeding
Part of Digestive system clinical trials.
This trial compares two tests (ROTEM and TEG) that help doctors decide which blood products to give to cirrhosis patients with active stomach or intestinal bleeding that is not from varices. The goal is to find which test works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (any cause)
- You are between 18 and 80 years old
- You have active bleeding from a non-variceal source in your upper digestive tract (confirmed by endoscopy)
- Your standard clotting tests show high INR (over 1.8) or low platelets (under 50,000)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
This study tracks people with liver cirrhosis to see how often portal vein thrombosis (a blood clot in the main vein to the liver) occurs and how it can be treated with blood thinners. It aims to improve care for those at risk of these clots.
This trial compares a surgery called LSD with a procedure called TIPS to see which is better at preventing rebleeding in people with liver cirrhosis and an enlarged spleen. It may help if you have had bleeding from veins in your esophagus or stomach that came back after treatment.
This trial tests whether using a slightly different target on a blood-clotting test (ROTEM) can reduce the need for blood transfusions in people with liver disease who need a procedure. If you have cirrhosis or ACLF with severe clotting problems, this study may help your doctors decide how much blood product to give you before the procedure.
This trial is testing if a special blood test called ROTEM can help doctors predict the risk of bleeding after high-risk procedures in people with cirrhosis. It aims to improve safety and guide treatment decisions.
This trial compares how well an artificial intelligence (AI) tool interprets ROTEM blood-clotting tests compared to human experts. The results could help doctors make faster and more accurate decisions about bleeding or clotting problems.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.